THURSDAY, February 11, 2021 (HealthDay News) – Individuals with overweight or obesity who received subcutaneous semaglutide plus lifestyle intervention once a week saw sustained, clinically relevant body weight reductions according to a study published online in New England on February 10th.
John PH Wilding, DM, of the University of Liverpool in the UK, and colleagues included 1,961 adults with a body mass index of 30 or more who did not have diabetes and randomly assigned them to either subcutaneous semaglutide or placebo for 68 weeks for 68 weeks plus lifestyle intervention in a ratio of 2: 1.
The researchers found that the mean change in body weight from baseline to week 68 in the semaglutide and placebo groups were -14.9 and -2.4 percent, respectively, an estimated treatment difference of -12.4%. corresponds. At week 68, more participants in the semaglutide group experienced weight loss of 5 percent or more (86.4 versus 31.5 percent), 10 percent or more (69.1 versus 12.0 percent), and 15 percent or more, compared to the placebo group (50.5 versus 50.5 percent) 4.9 percent). In terms of cardiometabolic risk factors, participants who received semaglutide showed greater improvement than participants who received placebo. The most common adverse events with semaglutide were nausea and diarrhea, which were typically transient, mild to moderate in severity, and decreased over time.
“The STEP 1 study (like its name) is a good start,” write the authors of an accompanying editorial. “However, as noted by the authors, there are concerns, including adverse events.”
The study was funded by Novo Nordisk, the maker of semaglutide.
Summary / full text (subscription or payment required)
Editorial (subscription or payment required)